Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Zimmer & ISTO to commence human trials of Neocartilage graft:

This article was originally published in Clinica

Executive Summary

Zimmer and ISTO Technologies have received investigational new drug (IND) approval in the US for Neocartilage, a living tissue-engineered graft for the repair of cartilage defects. The IND covers the restoration of joint function and relief of pain in the knee. The approval will allow the firms to proceed with human clinical trials of the product. Neocartilage was developed by St Louis, Missouri-based ISTO, which in 2002 granted exclusive marketing and distribution rights to Zimmer. The two companies have since collaborated on pre-clinical trials of the product. Neocartilage is a grown from juvenile chondrocytes (cartilage cells), using ISTO's proprietary cell-based platform technology.

You may also be interested in...

Big Win For EMA On Transparency

The European Court of Justice has confirmed the European Medicines Agency’s approach to disclosure of data submitted as part of a marketing authorization application. It is a big disappointment for industry, which nonetheless says it supports responsible data sharing and will support efforts to develop a balanced approach.

UK Biotech Financing Holds Up Despite Woodford and Brexit

Neil Woodford’s fall from grace and Brexit dragged on an otherwise buoyant sector

Dr Reddy’s Focuses On India And China

Dr Reddy’s sees its Indian domestic market and China as hot prospects as it pursues its “transformation journey” in which it is reducing its dependence on the slowing US market.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts